<DOC>
	<DOCNO>NCT01721759</DOCNO>
	<brief_summary>The purpose study assess objective response rate ( change tumor size baseline ) patient advance metastatic squamous cell nonsmall-cell lung cancer treat Nivolumab ( BMS-936558 ) failure 2 prior systemic regimen</brief_summary>
	<brief_title>Study Nivolumab ( BMS-936558 ) Patients With Advanced Metastatic Squamous Cell Nonsmall-cell Lung Cancer Who Have Received At Least 2 Prior Systemic Regimens</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com Men woman ≥18 year age Patients histologically cytologically document squamous cell nonsmallcell lung cancer present Stage IIIB/Stage IV disease ( accord version 7 International Association Study Lung Cancer Staging Manual Thoracic Oncology ) , recurrent progressive disease follow multimodal therapy ( radiation therapy , surgical resection , definitive chemoradiation locally advanced disease Eastern Cooperative Oncology Group Performance Status 0 1 Disease progression recurrence platinum doubletbased chemotherapy regimen least 1 additional systemic therapy Measurable disease compute tomography scan/magnetic resonance image per Response Evaluation Criteria Solid Tumors , volume 1.1 Untreated central nervous system ( CNS ) metastases . Metastases treat patient neurologically return baseline ( except residual sign symptom related CNS treatment ) least 2 week prior enrollment . In addition , patient must stop take corticosteroid take stable decrease dose ≤10 mg prednisone daily ( equivalent ) Carcinomatous meningitis Active know suspect autoimmune disease interstitial lung disease Prior treatment either arm study CA209017 CA184104 Prior therapy antiProgrammed death1 ( antiPD1 ) , antiProgrammed cell death ligand 1 ( antiPDL1 ) , antiProgrammed cell death ligand 2 ( antiPDL2 ) , antiCD137 , antiCytotoxic T lymphocyteassociated antigen 4 ( antiCTLA4 ) antibody , antibody drug specifically target Tcell costimulation checkpoint pathways A condition require systemic treatment corticosteroid immunosuppressive medication within 14 day first dose study drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>